Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofeno
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ibuprofeno is a nonsteroidal anti-inflammatory drug (NSAID) marketed by Pharmex (Pharmex Group). As a small molecule, it functions by reversibly inhibiting the cyclooxygenase enzymes COX-1 and COX-2. This inhibition prevents the conversion of arachidonic acid into prostaglandins, which are lipid mediators responsible for signaling pain, promoting inflammation, and inducing fever. Administered orally, this generic medication is used for the symptomatic treatment of various conditions, including mild to moderate pain, inflammatory disorders like arthritis, and febrile illnesses.
- Brand names
- Ibuprofeno Pharmex
- Other names
- ibuprofen
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on ibuprofeno.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofeno.